5th Circ. Frees Pfizer Unit, Others From Generic-Reglan Suit
Law360, New York (July 14, 2014, 9:23 PM EDT) -- The Fifth Circuit has issued the latest ruling in an injury suit over the generic form of the heartburn medicine Reglan, shielding branded pharmaceutical companies including Pfizer unit Wyeth LLC and Schwarz Pharma Inc. for injuries allegedly caused by generic versions of their drugs.
The federal appeals court on Friday affirmed a lower court’s ruling in favor of branded makers by invoking its 2012 Demahy ruling that Louisiana law does not expose branded drug manufacturers to liability in cases involving alleged injuries from generics. The ruling dealt a blow to plaintiff Tina Johnson, who like others in similar cases claimed she...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!